AR and prostate carcinoma: Pathological AR protein variants, yielding from gene alterations and abnormal splicing patterns, have been identified in human prostate cancer (47, 48) and have been shown to confer resistance to androgen therapies (48, 49), providing opportunities for the identification of promising therapeutic targets and prognostic markers (50–52).